Table 2 |
|||
|
Correlations of serum levels for BLyS and APRIL to lupus activity parameters, pathological scores, and renal and systemic involvement at baseline. |
|||
|
BLyS |
APRIL |
||
|
|
|||
|
Renal parameters |
|||
|
R_SLEDAI |
-0.17 |
0.22 |
|
|
Serum creatinine |
mg/dl |
0.06 |
0.06 |
|
Erythrocyturia |
cells/high power field |
-0.13 |
0.06 |
|
Urine protein |
g/day |
-0.05 |
0.44** |
|
Activity score |
-0.11 |
0.34* |
|
|
Chronicity score |
0.25 |
0.20 |
|
|
Lupus parameters |
|||
|
ANA titer |
-0.20 |
0.02 |
|
|
Anti-dsDNA titer |
-0.28 |
0.23 |
|
|
Complement factor 3 |
mg/dl |
0.46** |
-0.44** |
|
Total leukocyte count |
cells/mm3 |
-0.49*** |
0.26 |
|
Polymorph |
cells/mm3 |
-0.40** |
0.18 |
|
Lymphocyte |
cells/mm3 |
-0.42*** |
-0.14 |
|
Treatment |
|||
|
Prednisolone |
mg/day |
0.46*** |
0.25 |
|
Mycophenolate |
mg/day |
0.37** |
-0.09 |
|
|
|||
|
ANA, antinuclear antibody; APRIL, a proliferation-inducing ligand; BlyS, B lymphocyte activation protein; R_SLEDAI, renal Systemic Lupus Erythematous Disease Activity Index. *P < 0.05, **P < 0.01, ***P < 0.001. |
|||
|
Treamtrakanpon et al. Arthritis Research & Therapy 2012 14:R252 doi:10.1186/ar4095 |
|||
